Skip to main content
    M

    MacroGenics Inc (MGNX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.17
    -0.03 (-1.36%)

    Market Cap: $140.60M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    MacroGenics Inc (MGNX) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    MacroGenics (MGNX) trades at 1.2x sales and 5.5x book value. Its P/S of 1.2x is below its 5-year median of 2.2x. Its forward P/E is 61.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E61.0x
    Price to sales1.2x
    Price to book5.5x
    PEGN/A
    FCF yield-29.9%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 79.3% below 5.8x and its P/B is 96.4% above 2.8x.

    MultipleCurrent5-year median10-year median
    P/S1.2x2.2x5.8x
    P/B5.5x2.4x2.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 0.9x in 2025 to 12.4x in 2021. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$1.610.9x1.8x
    2024$3.251.4x1.8x
    2023$9.6210.1x3.9x
    2022$6.712.7x2.9x
    2021$16.0512.4x4.1x
    2020$22.8611.5x4.2x
    2019$10.888.2x2.3x
    2018$12.709.0x2.4x
    2017$19.004.4x2.3x
    2016$20.447.7x2.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MGNX

    What is MGNX's forward P/E ratio?

    MacroGenics has a forward P/E ratio of 61.0x.

    Is MGNX stock overvalued?

    GNG's valuation label for MGNX is Fairly valued.

    What is MGNX's price to sales ratio?

    MacroGenics has a price to sales ratio of 1.2x.